Literature DB >> 9618519

A strategy for organ allografts without using immunosuppressants or irradiation.

H Morita1, K Sugiura, M Inaba, T Jin, J Ishikawa, Z Lian, Y Adachi, S Sogo, K Yamanishi, H Taki, M Adachi, T Noumi, Y Kamiyama, R A Good, S Ikehara.   

Abstract

A strategy to achieve regular and long lasting organ and tissue allografts without using immunosuppressants and/or irradiation has been established for mice. One hundred percent of skin allografts can be induced to survive >350 days after transplantation if spleen cells from the same donors are first injected into the portal vein of the recipients. The mechanisms underlying this long-term tolerance induction can be described as follows: (i) donor T cells from the spleen of the donor facilitate the acceptance of the allogeneic engraftment, (ii) donor-specific anergy is induced in the cytotoxic T-lymphocytes of the recipients, (iii) T helper type 2 cells become the dominant T cells in the recipients that are accepting the skin transplants, and (iv) a lasting chimerism (microchimerism) is established in these recipients. This strategy, perhaps with minor modifications, might permit one also to overcome major barriers to organ allografting in humans. If this were the case, it could represent production of long lasting immunologic tolerance without need for irradiation or cytotoxic chemo-preparative regimen and as such could greatly facilitate allotransplantation free of episodes of chronic or acute rejection or toxic and damaging preparatory regimens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618519      PMCID: PMC22697          DOI: 10.1073/pnas.95.12.6947

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  Cell migration, chimerism, and graft acceptance.

Authors:  T E Starzl; A J Demetris; N Murase; S Ildstad; C Ricordi; M Trucco
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

2.  Immunosuppression induced by hepatic portal venous immunization spares reactivity in IL-4 producing T lymphocytes.

Authors:  R M Gorczynski
Journal:  Immunol Lett       Date:  1992-06       Impact factor: 3.685

3.  Permanent acceptance of liver allografts by intraportal injection of donor spleen cells in rats.

Authors:  Y Nakano; M Monden; L A Valdivia; M Gotoh; T Tono; T Mori
Journal:  Surgery       Date:  1992-06       Impact factor: 3.982

Review 4.  The immunology of experimental liver transplantation in the rat.

Authors:  N Kamada
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

5.  Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: possible explanation for the mechanism of tolerance induction by portal vein injection.

Authors:  Y Zhang; R Yasumizu; K Sugiura; F Hashimoto; Y Amoh; Z Lian; N Nishio; S Ikehara
Journal:  Eur J Immunol       Date:  1994-07       Impact factor: 5.532

6.  Successful pancreatic allografts in combination with bone marrow transplantation in mice.

Authors:  H Iwai; R Yasumizu; K Sugiura; M Inaba; T Kumazawa; R A Good; S Ikehara
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

7.  Specific tolerance induction and transplantation: a single-day protocol.

Authors:  A de Vries-van der Zwan; A C Besseling; L P de Waal; C J Boog
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

8.  Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease.

Authors:  T E Starzl; A J Demetris; M Trucco; C Ricordi; S Ildstad; P I Terasaki; N Murase; R S Kendall; M Kocova; W A Rudert
Journal:  N Engl J Med       Date:  1993-03-18       Impact factor: 91.245

9.  Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.

Authors:  H Mayumi; R A Good
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

View more
  6 in total

Review 1.  New strategies for BMT and organ transplantation.

Authors:  Susumu Ikehara
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Nonmyeloablative allogeneic bone marrow transplantation of a child with systemic autoimmune disease and lung vasculitis.

Authors:  Olcay Y Jones; Richard A Cahill
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Acceptance of skin allografts in pigs by portal venous injection of donor bone marrow cells.

Authors:  H Morita; N Nakamura; K Sugiura; S Satoi; Y Sakakura; W Tu; K Yoshida; M Oda; T Inoue; H Inui; T Nagahama; Y Kamiyama; S Ikehara
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

4.  In the Acute Phase of Trypanosoma cruzi Infection, Liver Lymphoid and Myeloid Cells Display an Ambiguous Phenotype Combining Pro- and Anti-Inflammatory Markers.

Authors:  Carina de Lima Pereira Dos Santos; Natalia Vacani-Martins; Cynthia Machado Cascabulho; Mirian Claudia de Souza Pereira; Ian Nicholas Crispe; Andrea Henriques-Pons
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

5.  Portal venous donor-specific transfusion in conjunction with sirolimus prolongs renal allograft survival in nonhuman primates.

Authors:  K K Dhanireddy; D A Bruno; T A Weaver; H Xu; X Zhang; F V Leopardi; D A Hale; A D Kirk
Journal:  Am J Transplant       Date:  2008-10-31       Impact factor: 8.086

6.  Development of a Safeguard System Using an Episomal Mammalian Artificial Chromosome for Gene and Cell Therapy.

Authors:  Narumi Uno; Katsuhiro Uno; Shinya Komoto; Teruhiko Suzuki; Masaharu Hiratsuka; Mitsuhiko Osaki; Yasuhiro Kazuki; Mitsuo Oshimura
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-15       Impact factor: 10.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.